ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"
Mr. Culley continued: "We now have in place the right team, the right programs and the opportunity to bring new therapies to patients with significant unmet needs in multiple therapeutic areas. This week's introduction of the MAST platform and our plans to develop ANX-188 for complications of arterial disease solidify our commitment to this franchise. Our new corporate identity embodies the fundamental changes that have taken place over the past several years and reflects that, in a very fundamental sense, we are a new company."
Details Regarding Name Change from
The following changes will be effective prior to trading on
- The Company's name will be "
Mast Therapeutics, Inc.".
- The Company's common stock will be traded on the NYSE MKT under the ticker symbol "MSTX" (currently, "ANX").
- A new CUSIP number of 576314 108 will be assigned to the Company's common stock and a new CUSIP number of 576314 116 will be assigned to the common stock purchase warrants of the Company that were issued in November 2011.
- The Company's website will be available at www.masttherapeutics.com (currently, www.adventrx.com).
- The Company's lead product candidate will be referred to as "MST-188" (currently, ANX-188).
Outstanding stock certificates and warrants for shares of the Company's common stock are not affected by the name change; they will continue to be valid and need not be exchanged.
The Company is recruiting subjects in EPIC, a pivotal phase 3 study of ANX-188 in sickle cell disease. The Company plans to initiate a phase 2 clinical study of ANX-188 in acute limb ischemia, a complication of peripheral arterial disease, in late 2013 or early 2014. More information can be found on the Company's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding ADVENTRX's development plans for ANX-188 in acute limb ischemia and other complications of arterial disease and the timing of activities related to those plans. Among the factors that could cause or contribute to material differences between ADVENTRX's actual results and expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the potential for delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing clinical trial material, completing manufacturing process development activities, and being subject to a "clinical hold"; the risk of suspension or termination of a clinical study, including due to lack of adequate funding or patient safety concerns; the potential for institutional review boards or the
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.
Ioana C. Hone, ADVENTRX Pharmaceuticals, +1-858-552-0866 Ext. 303, firstname.lastname@example.org
*Links to third-party Internet sites are provided on this site for your convenience. Such sites are not under our control. Linking to third-party Internet sites does not indicate or imply any endorsement of or sponsorship by us of such sites or the information, products or services offered on or through such sites. We expressly disclaim any responsibility for the privacy policies and information collection practices of such third-party sites, as well as the content, accuracy of information and/or quality of such sites, including any products and/or services provided by or advertised on such sites. You are responsible for complying with all terms and conditions governing the use of such third-party Internet sites.
Enter your e-mail address to receive alerts whenever certain new company information is posted to this site